Monitor for the definitive terms of the proposed securities issue. The lack of pricing details suggests the offering is still being structured; once filed, the size and pricing will determine the dilution magnitude. Given the company's precarious cash position, this raise is likely necessary for survival but will be highly dilutive to existing shareholders.
Price Chart
Executive Summary
Alterity Therapeutics filed a 6-K with an Exhibit 99.1 titled 'Proposed issue of securities - ATH', indicating a planned securities offering. The filing provides no financial figures, pricing, or terms of the proposed issue. Given the company's $44M market cap, pre-revenue status, and going-concern disclosure in its recent 20-F, this filing signals a dilutive capital raise to fund operations.
Key Facts
- Filed a 6-K with Exhibit 99.1 titled 'Proposed issue of securities - ATH'
- No specific terms, size, or pricing of the proposed securities were disclosed
- Company is a development-stage enterprise with no revenue and a going-concern warning from its August 2026 20-F
- Market cap is approximately $44M, making any offering potentially highly dilutive
Financial Impact
Undisclosed amount; likely a dilutive capital raise given the company's cash burn and going-concern status
Risk Factors
- Significant dilution from the proposed securities issuance
- Going-concern risk if the offering fails to raise sufficient capital
- No revenue or near-term commercialization prospects for lead candidate ATH434
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-033323 |
| Document: 0001437749-26-033323-index-headers.html | 0001437749-26-033323 |
| Document: 0001437749-26-033323-index.html | 0001437749-26-033323 |
| Document: 0001437749-26-033323.txt | 0001437749-26-033323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers